Real-world use of inhaled treprostinil for lung disease-pulmonary hypertension: A protocol for patient evaluation and prescribing

Shelsey W. Johnson; Lauren Finlay; Stephen C. Mathai; Ronald H. Goldstein; Bradley A. Maron

doi:10.1002/pul2.12126

Real-world use of inhaled treprostinil for lung disease-pulmonary hypertension: A protocol for patient evaluation and prescribing

Shelsey W. Johnson, Lauren Finlay, Stephen C. Mathai, Ronald H. Goldstein, Bradley A. Maron

School of Medicine

Research output: Contribution to journal › Letter › peer-review

Abstract

Inhaled treprostinil was approved recently for interstitial lung disease-pulmonary hypertension; however, efficacy in “real-world” populations is not known. We designed a protocol and report our experience evaluating 10 patients referred for therapy. Misdiagnosis at presentation was common; ultimately, three patients (30%) were prescribed drug. This protocol offers an opportunity to standardize longitudinal assessment of inhaled treprostinil in clinical practice.

Original language	English (US)
Article number	e12126
Journal	Pulmonary Circulation
Volume	12
Issue number	3
DOIs	https://doi.org/10.1002/pul2.12126
State	Published - Jul 2022

Keywords

Group 3 pulmonary hypertension
inhaled treprostinil
interstitial lung disease
pulmonary hypertension

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.1002/pul2.12126

Cite this

@article{6d937cd6861b4e87acb1ab5216dbb6bb,

title = "Real-world use of inhaled treprostinil for lung disease-pulmonary hypertension: A protocol for patient evaluation and prescribing",

abstract = "Inhaled treprostinil was approved recently for interstitial lung disease-pulmonary hypertension; however, efficacy in “real-world” populations is not known. We designed a protocol and report our experience evaluating 10 patients referred for therapy. Misdiagnosis at presentation was common; ultimately, three patients (30%) were prescribed drug. This protocol offers an opportunity to standardize longitudinal assessment of inhaled treprostinil in clinical practice.",

keywords = "Group 3 pulmonary hypertension, inhaled treprostinil, interstitial lung disease, pulmonary hypertension",

author = "Johnson, {Shelsey W.} and Lauren Finlay and Mathai, {Stephen C.} and Goldstein, {Ronald H.} and Maron, {Bradley A.}",

note = "Funding Information: Funding: Shelsey W. Johnson: NIH 5T32HL007035. Bradley A. Maron: R01HL139613-01, R01HL153502, R01HL155096-01; 2021A007243 BWH/MIT-Broad Institute; McKenzie Family Charitable Trust. Publisher Copyright: {\textcopyright} 2022 The Authors. Pulmonary Circulation published by Wiley Periodicals LLC on behalf of the Pulmonary Vascular Research Institute.",

year = "2022",

month = jul,

doi = "10.1002/pul2.12126",

language = "English (US)",

volume = "12",

journal = "Pulmonary Circulation",

issn = "2045-8932",

publisher = "John Wiley and Sons Inc.",

number = "3",

}

TY - JOUR

T1 - Real-world use of inhaled treprostinil for lung disease-pulmonary hypertension

T2 - A protocol for patient evaluation and prescribing

AU - Johnson, Shelsey W.

AU - Finlay, Lauren

AU - Mathai, Stephen C.

AU - Goldstein, Ronald H.

AU - Maron, Bradley A.

N1 - Funding Information: Funding: Shelsey W. Johnson: NIH 5T32HL007035. Bradley A. Maron: R01HL139613-01, R01HL153502, R01HL155096-01; 2021A007243 BWH/MIT-Broad Institute; McKenzie Family Charitable Trust. Publisher Copyright: © 2022 The Authors. Pulmonary Circulation published by Wiley Periodicals LLC on behalf of the Pulmonary Vascular Research Institute.

PY - 2022/7

Y1 - 2022/7

N2 - Inhaled treprostinil was approved recently for interstitial lung disease-pulmonary hypertension; however, efficacy in “real-world” populations is not known. We designed a protocol and report our experience evaluating 10 patients referred for therapy. Misdiagnosis at presentation was common; ultimately, three patients (30%) were prescribed drug. This protocol offers an opportunity to standardize longitudinal assessment of inhaled treprostinil in clinical practice.

AB - Inhaled treprostinil was approved recently for interstitial lung disease-pulmonary hypertension; however, efficacy in “real-world” populations is not known. We designed a protocol and report our experience evaluating 10 patients referred for therapy. Misdiagnosis at presentation was common; ultimately, three patients (30%) were prescribed drug. This protocol offers an opportunity to standardize longitudinal assessment of inhaled treprostinil in clinical practice.

KW - Group 3 pulmonary hypertension

KW - inhaled treprostinil

KW - interstitial lung disease

KW - pulmonary hypertension

UR - http://www.scopus.com/inward/record.url?scp=85138877565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85138877565&partnerID=8YFLogxK

U2 - 10.1002/pul2.12126

DO - 10.1002/pul2.12126

M3 - Letter

C2 - 36092795

AN - SCOPUS:85138877565

SN - 2045-8932

VL - 12

JO - Pulmonary Circulation

JF - Pulmonary Circulation

IS - 3

M1 - e12126

ER -

Real-world use of inhaled treprostinil for lung disease-pulmonary hypertension: A protocol for patient evaluation and prescribing

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this